Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
102.6 EUR | +1.03% | +0.69% | +8.85% |
Apr. 30 | GERRESHEIMER AG : Jefferies reaffirms its Buy rating | ZD |
Apr. 29 | Gerresheimer AG acquired minority stake in RxCap Inc. | CI |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The group shows a rather high level of debt in proportion to its EBITDA.
- With a 2024 P/E ratio at 24.54 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.85% | 3.75B | B+ | ||
-3.77% | 184B | C+ | ||
-1.77% | 107B | C | ||
-1.43% | 69.44B | A | ||
+2.06% | 50.37B | B- | ||
+9.43% | 44.82B | B- | ||
+3.40% | 41.53B | B+ | ||
+3.04% | 26.73B | B | ||
+4.64% | 26.84B | A- | ||
+15.23% | 25.71B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GXI Stock
- Ratings Gerresheimer AG